C:\Documents and Settings\EBernhardt\My Documents\Stnexp\Queries\10672949-2.str



Query too big to Preview

chain nodes :
7 8 9 10 11 12 13 29 30 31 32 33 34 35 36 50
ring nodes :
1 2 3 4 5 6 18 19 20 21 22 23 24 25 26 40 41 42 43 44
45 46 47 48 49
chain bonds :
1-33 1-34 2-7 3-31 3-32 4-29 4-30 5-20 6-35 6-36 7-8 7-9 7-10
10-11 11-13 11-12 11-50
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 18-19 18-22 19-20 20-21 21-22 21-23
22-26 23-24 24-25 25-26 40-41 40-45 41-42 42-43 43-44 44-45
44-46 45-49 46-47 47-48 48-49
exact/norm bonds :
1-2 1-6 1-33 1-34 2-3 2-7 3-4 3-31 3-32 4-5 4-29 4-30 5-6
5-20 6-35 6-36 7-8 7-9 7-10 10-11 11-13 11-12 11-50 18-19
18-22 19-20 20-21 44-46 45-49 46-47 47-48 48-49
normalized bonds :
21-22 21-23 22-26 23-24 24-25 25-26 40-41 40-45 41-42 42-43
43-44 44-45
isolated ring systems :
containing 18 :

G1:O,S,N

G2:H,CH3

G3:C,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 29:CLASS 30:CLASS
31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 40:Atom
41:CLASS 42:Atom 43:Atom 44:Atom 45:Atom 46:Atom 47:Atom 48:Atom
49:Atom 50:CLASS

isolated ring systems :
containing 18 :

G1:O,S,N

G2:H,CH3

G3:C,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom
24:Atom 25:Atom 26:Atom 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS
34:CLASS 35:CLASS 36:CLASS 40:Atom 41:CLASS 42:Atom 43:Atom 44:Atom 45:Atom
46:Atom 47:Atom 48:Atom 49:Atom 50:CLASS

L5 STRUCTURE UPLOADED

=> s l5
SAMPLE SEARCH INITIATED 18:45:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 41 TO ITERATE

100.0% PROCESSED 41 ITERATIONS 12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 436 TO 1204
PROJECTED ANSWERS: 32 TO 446

L6 12 SEA SSS SAM L5

=> d l6 1 5 10

L6 ANSWER 1 OF 12 REGISTRY COPYRIGHT 2005 ACS on STN
RN 860023-06-9 REGISTRY
ED Entered STN: 12 Aug 2005
CN Quinoline, 1-acetyl-1,2,3,4-tetrahydro-6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-3,3-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-[6-[2-[4-(1H-Indazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-3,4-dihydro-2H-quinolin-1-yl]ethanone dihydrochloride
MF C26 H33 N5 O . 2 Cl H
SR CA
LC STN Files: CA, CAPLUS
CRN (860116-21-8)



●2 HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 5 OF 12 REGISTRY COPYRIGHT 2005 ACS on STN
RN 676117-88-7 REGISTRY
ED Entered STN: 18 Apr 2004
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-1-pentyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-1-pentyl-3,4-dihydro-1H-quinolin-2-one
FS 3D CONCORD
MF C30 H40 N4 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 10 OF 12 REGISTRY COPYRIGHT 2005 ACS on STN
RN 676115-73-4 REGISTRY
ED Entered STN: 18 Apr 2004
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one
FS 3D CONCORD
MF C24 H28 N4 O2

SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s l5 sss full
FULL SEARCH INITIATED 18:45:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 880 TO ITERATE

100.0% PROCESSED 880 ITERATIONS 315 ANSWERS
SEARCH TIME: 00.00.01

L7 315 SEA SSS FUL L5

=> save l7
ENTER NAME OR (END):ten672949/a
ANSWER SET L7 HAS BEEN SAVED AS 'TEN672949/A'

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.71	342.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.46

FILE 'CAPLUS' ENTERED AT 18:46:21 ON 30 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Sep 2005 VOL 143 ISS 15

FILE LAST UPDATED: 29 Sep 2005 (20050929/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l7
L8 12 L7

=> d l8 1-12 bib abs fhitstr

L8 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:638875 CAPLUS
DN 143:153404
TI Preparation of N-substituted piperidine and piperazine derivatives dopamine D2 and serotonin 2A receptor antagonists
IN Cho, Stephen Sung Yong; Gregory, Tracy Fay; Guzzo, Peter Robert; Howard, Harry Ralph, Jr.; Nikam, Sham Shridhar; Surman, Matthew David; Walters, Michael Anthony
PA Warner-Lambert Company Llc., USA
SO PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005066165	A1	20050721	WO 2004-IB4239	20041220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-533761P	P	20031231		

GI



I



II

AB This invention relates to N-substituted piperidine and piperazine derivs. (shown as I; variables defined below; e.g. [5-[2-[4-(benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-2,3-dihydroindol-1-yl](4-fluorophenyl)methanone (shown as II)), pharmaceutical compns. contg. them and their use in the treatment of central nervous system and other disorders. Although the methods of prepn. are not claimed, example prepns. and/or characterization data for .apprx.160 I are included. For example, II was prepd. in 98 % yield by coupling 3-[4-[2-(3,3-dimethyl-2,3-dihydro-1H-indol-5-yl)ethyl]piperazin-1-yl]benzo[d]isothiazole with 4-fluorobenzoyl chloride; the benzo[d]isothiazole reactant was prepd. in 79 % yield by redn. of 5-[2-[4-(benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-1,3-dihydroindol-2-one, which was prepd. in 96 % yield from 3-(piperazin-1-yl)benzo[d]isothiazole and 5-(2-chloroethyl)-3,3-dimethyl-1,3-dihydroindol-2-one, which was prepd. in 45 % yield by redn. of 5-(2-chloroethyl)-3,3-dimethyl-1,3-dihydroindol-2-one, which was prepd. in >96 % yield from chloroacetyl chloride and 3,3-dimethyl-1,3-dihydroindol-2-one. For I: M = E-R9, L-T-R9, T-D-R9; U is S, O, SO, SO2, CH2 or NR3; V is N or C; Z is N or C; A is -(CH2)mO-, -(CH2)mNR4-, or -(CH2)mC(R5R6)-, wherein R5 and R6 = H, (C1-C4) alkyl (un)substituted with 1-3 F atoms, (C1-C4) alkoxy (un)substituted with 1-3 F atoms, hydroxy, and aminoalkyl; or R5 and R6 together form a carbonyl, and wherein m = 1-4. R1 and R2 = H, (C1-C4) alkyl (un)substituted with 1-3 F atoms, (C1-4) alkoxy (un)substituted with 1-3 F atoms, halogen, nitro, cyano, amino, (C1-C4) alkylamino and di(C1-C4) alkylamino; R3 and R4 = H, (C1-C4) alkyl (un)substituted with 1-3 F atoms and (C1-C4) alkoxy (un)substituted with 1-3 F atoms; or, when U is NR3, one of R1 and R2 can form, together with the C to which it is attached, and together with R3 and the N to which it is attached, a heterocyclic ring contg. 4-7 ring members of which 1-3 ring members can be N, O and S, and of which the remaining ring members are C, with the proviso that when R3 forms a ring with one of R1 and R2, the other of R1 and R2 is absent. X is -[C(R11)(R12)]o-, wherein R11 and R12 = H and (C1-C4) alkyl (un)substituted with 1-3 F atoms, and wherein o = 0-3, with the proviso that when W is absent, o .gtoreq.2; W is -[C(R13)(R14)]p-, wherein R13 and R14 = H and (C1-C4) alkyl (un)substituted with 1-3 F atoms, and wherein p = 0-4, with the proviso that when X is absent, p .gtoreq.2; R7 and R8 = halo, R1 and -OR1; or R7,

when attached to a C adjacent to one of the C atoms shared by both the Ph ring to which R7 is attached and the ring contg. W, N and X, forms, together with a C atom of X or a C atom of W, a satd. carbocyclic ring contg. 3-6 C atoms. R9 = Ph, phenoxy, benzyloxy, and phenylamino, wherein the Ph moieties are (un)substituted with 1-3 halo, (C1-C3) alkyl (un)substituted with 1-3 F atoms, (C1-C3) alkoxy (un)substituted with 1-3 F atoms, nitro, cyano, amino, and (C1-C3) alkylamino; or R9 is a pyrrolidine, piperidine or morpholine ring wherein the point of attachment to D, T or E is the ring N, and wherein said pyrrolidine, piperidine or morpholine ring can be (un)substituted with 1 or 2 Me, amino, (C1-04) alkylamino, and di(C1-C4) alkylamino; or R9 is a furan, thiophene, or pyrazole ring (un)substituted with 1-2 (C1-C4) alkyl groups; or R9 is (C1-C6) straight or branched alkyl or (C3-C6) cycloalkyl, wherein said straight, branched and cyclic alkyl moieties are be (un)substituted with 1-3 halo atoms or (C1-C4) alkoxy (un)substituted with 1-3 F atoms; or R9 is halogen, nitro, cyano, amino, (C1-C4) alkylamino, di(C1-C4) alkylamino or OR1, wherein the alkyl moieties of (C1-C4) alkylamino and di(C1-C4) alkylamino are (un)substituted with an amino, (C1-C4) alkylamino, or di(C1-C4) alkylamino group; E is -C(O)-, -S(O)- or -SO2-; T is -C(O)- or -CO2-; L is -(CH2)n wherein n = 0-3; D is -(CHR10)q-, wherein q = 1-3, or NR10; R10 is H or straight or branched (C1-C3) alkyl.

IT **860023-07-0P**, 1-[6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-7-chloro-4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl]ethanone
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; prepn. of N-substituted piperidine and piperazine derivs. dopamine D2 and serotonin 2A receptor antagonists)

RN 860023-07-0 CAPLUS

CN Quinoline, 1-acetyl-6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-7-chloro-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:756696 CAPLUS

DN 141:260561

TI A preparation of focused library of quinolinecarboxylic acid derivatives, useful as caspase enzyme inhibitors

IN Ivashchenko, Alexander Vasilievich; Kobak, Vladimir Vasilievich; Kysil, Volodymyr Mikhailovich; Kuzovkova, Yulia Aleksandrovna; Ilyin, Alexey Petrovich; Kravchenko, Dmitri Vladimirovich; Tkachenko, Sergey Yevgenievich; Khvat, Alexander Viktorovich; Okun, Ilya Matusovich

PA Chemical Diversity Research Institute, Ltd., Russia

SO PCT Int. Appl., 182 pp.
CODEN: PIXXD2

DT Patent
LA Russian
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004078731	A1	20040916	WO 2004-RU81	20040303
	W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	RU 2229475	C1	20040527	RU 2003-106182	20030306
	RU 2260002	C2	20050910	RU 2003-124470	20030808
	RU 2257385	C2	20050727	RU 2003-125937	20030826
PRAI	RU 2003-106182	A	20030306		
	RU 2003-124470	A	20030808		
	RU 2003-125937	A	20030826		

OS MARPAT 141:260561
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a prepn. of focused library of quinolinecarboxylic acid derivs. of formulas I, II, and III [wherein: R1 is H, halogen, CF3, CN, NO2, or OH, etc.; R2 is halogen, (un)substituted alkyl, NH2, or OH; R3 is H, halogen, alk(en)yl, (un)substituted NH2 or OH; R4 is H, CO2H, or C(O)NH2; R5 is (un)substituted hydroxy- or mercapto-group, NH2, or heterocycle, etc.; R6 is H or other inert substituent; R7 is H, CN, CF3, NO2, NH2, alkylsulfonyl, or hydroxysulfonyl, etc.; W is O, NH, or N-alkyl, etc.], useful as caspase enzyme inhibitors (no biol. data). For instance, quinolinecarboxylate deriv. IV was prepd. via esterification of quinolinecarboxylic acid deriv. V by 2-FC6H4CH2Br with a yield of 74% (example 5).

IT **591242-64-7P**
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(prepn. of focused library of quinolinecarboxylic acid derivs. useful as caspase enzyme inhibitors)

RN 591242-64-7 CAPLUS
CN 4-Quinolinecarboxylic acid, 2-methyl-, 2-[4-(1,1-dioxido-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:412926 CAPLUS
DN 140:423706
TI Preparation of phenylalkyl and pyridylalkyl piperazine derivatives as antagonists of dopamine D2 receptors and of serotonin 2A (5HT2A) receptors
IN Cho, Stephen Sung Yong; Davis, Jamie Marie; Graham, James Michael; Gregory, Tracy Fay; Howard, Harry Ralph, Jr.; Nikam, Sham Shridhar; Walters, Michael Anthony
PA Warner-Lambert Company LLC, USA
SO PCT Int. Appl., 185 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041793	A1	20040521	WO 2003-IB4805	20031027
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2505397	AA	20040521	CA 2003-2505397	20031027
	EP 1562919	A1	20050817	EP 2003-753871	20031027
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2004186108	A1	20040923	US 2003-703333	20031107
PRAI	US 2002-425219P	P	20021108		
	WO 2003-IB4805	W	20031027		

OS MARPAT 140:423706
GI



I



II



III

AB The title compds. [I; M = N(R2)WR3, II; R1 = (un)substituted 1,2-benzisothiazoyl, 1,2-benzisoxazoyl, pyridyl, etc.; A = (CH2)n(CH2); n = 0-3; U = C, N; m = 1-2; X1-X3 = H, halo, alkyl, etc.; R2 = H, alkyl, arylalkyl, etc.; W = CO, CO2, CONH, SO2, SO2NR4; R3, R4 = alkyl, arylalkyl, alkenyl, etc.], useful in the treatment of central nervous system and other disorders, were prepd. Thus, amidation of 4-[2-(4-1,2-benzisothiazol-3-ylpiperazin-1-yl)ethyl]phenylamine with trimethylacetyl chloride in the presence of Et3N in THF afforded the amide III. The exemplified compds. I showed IC50 values of .ltoreq. 1 .mu.M in dopamine D2 receptor binding assay and in serotonin 2A binding assay. The pharmaceutical compn. comprising the compd. I is claimed.

IT **690976-58-0P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenylalkyl and pyridylalkyl piperazines as antagonists of dopamine D2 receptors and of serotonin 2A (5HT2A) receptors)

RN 690976-58-0 CAPLUS

CN 8-Quinolinesulfonamide, N-[4-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:287843 CAPLUS
DN 140:321381
TI Preparation of heterocyclic substituted piperazines for the treatment of schizophrenia
IN Davis, Jamie Marie; Gregory, Tracy Fay; Walters, Michael Anthony
PA Warner-Lambert Company Llc, USA
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004029048	A1	20040408	WO 2003-IB4113	20030918
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2500115	AA	20040408	CA 2003-2500115	20030918
	EP 1546145	A1	20050629	EP 2003-798314	20030918
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003014796	A	20050726	BR 2003-14796	20030918
	US 2004067960	A1	20040408	US 2003-672949	20030926
PRAI	US 2002-413839P	P	20020926		
	WO 2003-IB4113	W	20030918		

OS MARPAT 140:321381
GI



I

AB The title compds. [I; Ar = 1,2-benzisothiazoyl, 1,2-benzisothiazoyl -1-oxide, naphthyl, pyridyl, etc.; with the proviso that Ar can not be attached to the piperazine ring via a Ph ring of Ar; Y = N, CH; A = (CH2)nCH2 (wherein n = 1-4, one of the CH2 groups that is not adjacent to the piperazine nitrogen can be replaced by an oxygen atom); R2, R3 = H, alkyl, fluoroalkyl, alkoxy, etc.; Q = (un)satd. (un)substituted 5-7 membered monocyclic heterocyclic ring contg. 1-3 heteroatoms selected from O, N and S], useful in the treatment of central nervous system disorders, were prepd. Thus, reacting 3-methylbut-2-enoic acid (2-{2-[4-(1,2-

benzisothiazol-3-yl)-piperazin-1-yl]ethyl}phenyl)amide (prepn. given) with AlCl3 in C6H5Cl afforded 8-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one which showed Ki of .ltoreq. 1 .mu.M against dopamine D2 receptor binding, and Ki of .ltoreq. 1 .mu.M against 5-HT2A receptor binding. The pharmaceutical compn. comprising the compd. I is claimed.

IT **677708-42-8P**
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclic substituted piperazines for the treatment of schizophrenia)

RN 677708-42-8 CAPLUS

CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-benzoyl-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:267327 CAPLUS
DN 140:287412
TI Preparation of piperazines as dopamine D2 and serotonin 5HT2A receptors inhibitors for the treatment of central nervous system disorders, in particular schizophrenia
IN Andreana, Tonja Lynn; Cho, Stephen Sung Yong; Graham, James Michael; Gregory, Tracy Fay; Howard, Harry Ralph, Jr.; Kornberg, Brian Edward; Nikam, Sham Shridhar; Pflum, Derek Andrew
PA Warner-Lambert Company LLC, USA
SO PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004026864	A1	20040401	WO 2003-IB3902	20030905

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	CA 2499326	AA	20040401	CA 2003-2499326	20030905
	EP 1546143	A1	20050629	EP 2003-797433	20030905
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003014393	A	20050719	BR 2003-14393	20030905
	US 2004138230	A1	20040715	US 2003-660908	20030912
PRAI	US 2002-411475P	P	20020917		
	US 2002-416355P	P	20021004		
	WO 2003-IB3902	W	20030905		

OS MARPAT 140:287412
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X =S, O, SO, SO2, CH2, NH and derivs.; Y, Z = independently N or CH; A = (CH2)mCH2, (CH2)mO, (CH2)mNR9, (CH2)mC(R7R8); R7, R8 = independently (un)substituted alkyl, alkoxy, or CR7R8 = carbonyl; m = 1-4; R4, R5 = independently H, (un)substituted alkyl, alkoxy, or when X = NR6 and derivs., CR4R5R6N = 4-7 membered heterocyclyl ring, with the proviso that when R9R4 or R9R5 = a ring, the other of R4 and R5 is absent; R9 = H, (un)substituted alkyl, alkoxy; R6 = H, (un)substituted alkyl, alkoxy; R1 = H, (un)substituted alkyl; R2, R3 = independently H, halo, hetero/aryl, (un)substituted aryl/heteroarylalkyl, alkoxy, etc.; V, W = independently CH2 and derivs. or CH and derivs.; and their pharmaceutically acceptable salts] were prepd. s dopamine D2 and serotonin 5HT2A receptors inhibitors for treating central nervous system disorders, in particular schizophrenia (no data). For example, II.bul.MeSO3H was prepd. by acylation of 3-chloro-2-methylaniline with 3,3-diethylacryloyl chloride, one-pot Friedel-Craft alkylation with chloroacetyl chloride and cyclization in the presence of AlCl3 to chloroacetylquinoline intermediate, redn. to chloroethylquinoline III, alkylation of 3-(piperazin-1-yl)benzo[d]isothiazole hydrochloride with III, followed by salt formation of II with methanesulfonic acid. II acted as dopamine D2 and serotonin 5HT2A receptors inhibitors with a Ki value of 0.9 nm and 1 nM, resp. Thus, I and their formulations are useful for treating central nervous system disorders, in particular schizophrenia and depression.

IT **676117-35-4P**, 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetamide
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of piperazines for treating of central nervous system disorders, in particular schizophrenia)

RN 676117-35-4 CAPLUS
CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl-2-oxo- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:732486 CAPLUS
DN 138:331185
TI New 3-benzisothiazolyl and 3-benzisoxazolylpiperazine derivatives with atypical antipsychotic binding profile
AU Orjales, Aurelio; Mosquera, Ramon; Toledo, Antonio; Pumar, Carmen; Labeaga, Luis; Innerarity, Ana
CS Research Department, FAES FARMA, S.A., Leioa, E-48940, Spain
SO European Journal of Medicinal Chemistry (2002), 37(9), 721-730
CODEN: EJMCA5; ISSN: 0223-5234
PB Editions Scientifiques et Medicales Elsevier
DT Journal
LA English
OS CASREACT 138:331185
AB New 3-benzisothiazolyl and 3-benzisoxazolylpiperazine derivs. were synthesized and their 5-HT1A, 5-HT2A and D2 receptor binding affinities evaluated. The compds. displayed high affinity for the 5-HT2A receptor combined with moderate to low 5-HT1A and D2 affinities. Two of them have been selected for further pharmacol. studies to be evaluated as potential atypical antipsychotics.
IT **516509-59-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzisothiazolyl and benzisoxazolylpiperazine derivs. with atypical antipsychotic binding profile)
RN 516509-59-4 CAPLUS
CN 2(1H)-Quinolinone, 1-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:10184 CAPLUS
DN 130:38398
TI Quinolin-2(1H)-one derivatives as serotonin antagonists
IN McCort, Gary; Hoornaert, Christian; Duclos, Olivier; Cadilhac, Caroline; Guilpain, Eric
PA Synthelabo S. A., Fr.
SO Fr. Demande, 38 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2761067	A1	19980925	FR 1997-3388	19970320
	FR 2761067	B1	19990423		
PRAI	FR 1997-3388		19970320		

OS MARPAT 130:38398
GI



I



HCl

II

AB Quinolinones I [R1, R2 = H, halogen, NH2, OH, NO2, CN, alkyl, alkoxy, CF3, OCF3, CO2R5, carbamoyl, SR5, SO2R5, NHNCOR5, NHSO2R5, NR52 (R5 = alkyl); R3 = H, (un)substituted alkyl; R4 = H, halogen, OH, NO2, CN, alkyl, alkoxy, CF3, CONH2, NHSO2Me; m = 2-4; Z = N, CH; A = O, NH, S, NR5] were prepd. for use as serotonin antagonists (no data). Thus, the quinolinone II was obtained from the chloroethylquinolinone and the piperidinylisoxazole fragments.

IT **216674-97-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of quinolinone derivs. as serotonin antagonists)

RN 216674-97-4 CAPLUS

CN 2(1H)-Quinolinone, 7-fluoro-4-[2-[4-(6-fluoro-1H-indazol-3-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:656492 CAPLUS

DN 126:8030

TI Synthesis and Evaluation of Heterocyclic Carboxamides as Potential

Antipsychotic Agents

AU Norman, Mark H.; Navas, Frank, III; Thompson, James B.; Rigdon, Greg C.

CS Division of Chemistry, Glaxo Wellcome Inc., Research Triangle Park, NC, 27709, USA

SO Journal of Medicinal Chemistry (1996), 39(24), 4692-4703
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB Heterocyclic analogs of 1192U90, 2-amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)benzamide hydrochloride (1), were prepd. and evaluated as potential antipsychotic agents. These analogs were evaluated in vitro for their binding to the dopamine D2, serotonin 5-HT2, and serotonin 5-HT1a receptors and in vivo for their ability to antagonize the apomorphine-induced climbing response in mice. Nine different types of heterocyclic carboxamides were studied in this investigation (i.e., pyridine-, thiophene-, benzothiophene-, quinoline-, 1,2,3,4-tetrahydroquinoline-, 2,3-dihydroindole-, indole-, benzimidazole-, and indazolecarboxamides). Two derivs. exhibited potent in vivo activities comparable to 1: 3-amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-2-pyridinecarboxamide (16) and 3-amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-2-thiophenecarboxamide (29). Furthermore, these derivs. were found to be much less active in behavioral models predictive of extrapyramidal side effects than in the mouse climbing assay, which predicts antipsychotic activity. Carboxamides 16 and 29 were selected for further evaluation as potential backup compds. to 1.

IT **161940-16-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of benzisothiazolylpiperazinylbutyl heterocyclic carboxamide antipsychotics)

RN 161940-16-5 CAPLUS

CN 8-Quinolinecarboxamide, N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:682542 CAPLUS

DN 123:83356

TI Preparation of 3-(1-piperazinyl)-1,2-benzisothiazole derivatives with antipsychotic effect

IN Fukuda, Yoshimasa; Sasaki, Toshiro; Nakatani, Yuuko; Ichimaru, Yasuyuki; Imanishi, Taiichiro

PA Meiji Seika K. K., Japan

SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2

DT Patent

LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9418197	A1	19940818	WO 1994-JP159	19940203
	W: CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 635506	A1	19950125	EP 1994-905841	19940203
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	CN 1103534	A	19950607	CN 1994-190042	19940203
	CN 1050604	B	20000322		
	US 5599815	A	19970204	US 1994-318857	19941220
PRAI	JP 1993-17505	A	19930204		
	WO 1994-JP1	A	19940104		
	WO 1994-JP159	W	19940203		

OS MARPAT 123:83356
GI



I



AB Compds. represented by general formula [I; n = 2-4; W = heterocyclyl, e.g., Q - Q2; m = 0-2; A = CH2, CH, N, NH; B = CH2, CH, N, NH, S; provided that both A and B .noteq. N or NH; X = CH, N, S, bond; Y = CH, N; R1 = H, halo, lower (halo)alkyl, (un)substituted Ph, OH, NO2, lower alkoxy, NH2, cyano; R2, R3 = H, halo, lower (halo)alkyl or alkoxy, NH2, cyano, provided that when X = bond, R2 is not present; or R2R3 = (CH2)p (wherein p = 3-5)] and pharmacol. acceptable salts thereof, reduced in the adverse effect against the extrapyramidal system and hence useful as an antipsychotic agent with few side effects, are prepd. Thus, 0.29 g 2-hydroxyquinoline was dissolved in DMF and treated with 80 mg NaH at 60.degree. for 30 min with stirring followed by cooling the reaction mixt. to room temp. and adding 2.16 g 1,4-dibromobutane and the resulting mixt. was stirred at 60.degree. for 4 h to give 64% 1-(4-bromobutyl)-2(1H)-quinolinone (II). II 0.56, 3-(1-piperazinyl)-1,2-benzisothiazole 0.44, and K2CO3 0.33 g were suspended in DMF and stirred at room temp. for 12 h to give 80% title compd. I (n = 4, W = 2-oxo-1,2-dihydro-1-quinolinyl). II (n = 4, W = 9-carbazolyl) and II (n = 3, W = 2-oxo-1,2-dihydro-1-quinolinyl) showed ED50 of 1.15 and 0.92 mg/kg i.p., resp., for inhibiting methamphetamine-induced spontaneous movement of mice (vs. 0.16 and 1.05

mg/kg i.p. for haloperidol and chlorpromazine, resp.) and induced catalepsy in mice at ED50 of >100 and 83.3 mg/kg i.p. in mice (vs. 1.3 and 6.2 mg/kg i.p. for haloperidol and chlorpromazine, resp.).

IT **165109-31-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of [N-(heterocyclylalkyl)piperazinyl]benzisothiazole derivs. as antipsychotics)

RN 165109-31-9 CAPLUS

CN 2(1H)-Quinolinone, 1-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L8 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:657604 CAPLUS
DN 123:55870
TI Preparation of indazole derivatives as antipsychotics
IN Sasaki, Toshiro; Nakatani, Juko; Hiranuma, Toyoichi; Kashima, Hiroko; Fukuda, Yoshimasa
PA Meiji Seika Co, Japan
SO Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07033744	A2	19950203	JP 1993-204612	19930727
PRAI	JP 1993-204612		19930727		

OS MARPAT 123:55870
GI



I



II

AB The title compds. I [n = 2 - 6; V = H, halo; R1 = H, alkyl, etc.; W = heterocycle (further details on said heterocycle are given)] are prepd. Indazole deriv. II (prepn. given) showed ED50 of 0.50 mg/Kg i.p. against methamphetamine-induced activities in mice, vs. ED50 of 0.16 mg/Kg i.p. shown by haloperidol. In a test for catalepsy-causing activity in mice, II showed ED50 of 18 mg/Kg i.p., vs. ED50 of 1.3 mg/Kg i.p. shown by haloperidol.

IT **164519-46-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indazole derivs. as antipsychotics)

RN 164519-46-4 CAPLUS

CN 6(5H)-Phenanthridinone, 5-[4-[4-(1H-indazol-3-yl)-1-piperazinyl]butyl]-(9CI) (CA INDEX NAME)



L8 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:464322 CAPLUS

DN 122:214060

TI Preparation of [(benzisothiazolylpiperazinyl)butyl]pyridinecarboxamides and related compounds as antipsychotics.

IN Norman, Mark Henry; Navas, Frank, III

PA Wellcome Foundation Ltd., UK
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9418196	A1	19940818	WO 1994-GB265	19940210
	W: AU, BG, CA, CN, CZ, FI, HU, JP, KR, NZ, RO, RU, SK, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	ZA 9400891	A	19950810	ZA 1994-891	19940209
	CA 2155758	AA	19940818	CA 1994-2155758	19940210
	AU 9460051	A1	19940829	AU 1994-60051	19940210
	EP 683778	A1	19951129	EP 1994-906290	19940210
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1117731	A	19960228	CN 1994-191142	19940210
	JP 08506337	T2	19960709	JP 1994-517819	19940210
	HU 73654	A2	19960930	HU 1995-1881	19940210
	FI 9503777	A	19950809	FI 1995-3777	19950809
PRAI	GB 1993-2622	A	19930210		
	WO 1994-GB265	W	19940210		

OS MARPAT 122:214060
GI



I

AB Title compds. [I; Y = heteroaryl group optionally substituted by .gtoreq.1 halo, nitro, alkyl, alkoxy, aryloxy, arylalkylenoxy, OH, SOnR2 or SOnN(R2)2, CN, CON(R2)2, COR2, CO2R2, CO-aryl, azido, N(R2)2, NR2N(R2a)2, NR2N:C(R2a)2, NR2(C:O)CH(N(R2a)2)R2b, NR2(C:O)R2a, NR2CO2R2a, alkoxycarbonylamino, PhN:N; with the proviso that Y does not include benzisothiazolyls or benzisoxazolyis; n = 0-2; V = O, S; Z = alkylene optionally interrupted by O, SOn, alkenylene, alkynylene; X = N, CR3, COR3; A = CR4, N; B = O, NR5, SOn; R1 = H, halo, NO2, cyano, N(R6)2, alkoxy, aryloxy, arylalkenyloxy, COR6; R, R2, R2a, R2B, R3, R4, R5, R6 = H, alkyl], and salts, solvates, N-oxides, and physiol. functional derivs. thereof, were prepd. Thus, 3-[4-(4-aminobutyl)-1-piperazinyl]-1,2-benzisothiazole (prepn. given) in CHCl3 was treated with Me3Al and then with Me 3-amino-2-thiophenecarboxylate; the mixt. was heated at 45-50.degree. for 5 days to give 3-amino-N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-2-thiophenecarboxamide, isolated as the hydrochloride. The latter antagonized apomorphine-induced climbing in mice with ED50 = 9.7 mg/kg orally.

IT **161940-16-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of [(benzisothiazolylpiperazinyl)butyl]pyridinecarboxamides and related compds. as antipsychotics)

RN 161940-16-5 CAPLUS

CN 8-Quinolinecarboxamide, N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1991:492295 CAPLUS

DN 115:92295

TI Preparation of heteroarylpiperazines as antipsychotic agents

IN Howard, Harry R.

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 409435	A1	19910123	EP 1990-307166	19900629
	EP 409435	B1	19941026		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 9100863	A1	19910124	WO 1989-US2954	19890707
	W: FI, HU, NO, RO, SU, US				
	ES 2062374	T3	19941216	ES 1990-307166	19900629
	JP 03044388	A2	19910226	JP 1990-176120	19900703
	JP 07017633	B4	19950301		
	CA 2020611	AA	19910108	CA 1990-2020611	19900706
	US 5350747	A	19940927	US 1992-836019	19920220
PRAI	WO 1989-US2954	A	19890707		

OS MARPAT 115:92295

GI



I



II



III



IV

AB The title compds. [I; W1 = CR2R3; W2 = CR4R5; W3 = CR6R7; 1 of W1-W3 may be absent; R1 = (substituted) benzisoxazolyl, benzisothiazolyl, benzopyrazolyl; R2-R7 = H, alkyl, 2 of them may form alkylene, alkenylene; X1 = H, halo, C1-4 alkyl, alkoxy, NO2, cyano, etc.; Y1 = H, C1-4 alkyl, (substituted) Ph, etc.; X1Y1 = heterocyclyl; Z = C1-6 alkylene], useful as antipsychotic agents (no data), were prepd. A mixt. of piperazine deriv. II, quinolinone III (prepn. given), Na2CO3, and KI in MIBK was heated at 90.degree. under N to give 13% title compd. IV, sepd. as HCl.1/2 H2O. Also prepd. were 17 addnl. I and numerous intermediates.

IT **133999-10-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antipsychotic agent)

RN 133999-10-7 CAPLUS

CN 2(1H)-Quinolinone, 7-chloro-3,4-dihydro-6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4,4-dimethyl- (9CI) (CA INDEX NAME)



=> d l8 4 5 12 bib abs hitstr

L8 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:287843 CAPLUS
DN 140:321381
TI Preparation of heterocyclic substituted piperazines for the treatment of schizophrenia
IN Davis, Jamie Marie; Gregory, Tracy Fay; Walters, Michael Anthony
PA Warner-Lambert Company Llc, USA
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004029048	A1	20040408	WO 2003-IB4113	20030918
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2500115	AA	20040408	CA 2003-2500115	20030918
	EP 1546145	A1	20050629	EP 2003-798314	20030918
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003014796	A	20050726	BR 2003-14796	20030918
	US 2004067960	A1	20040408	US 2003-672949	20030926
PRAI	US 2002-413839P	P	20020926		
	WO 2003-IB4113	W	20030918		

OS MARPAT 140:321381
GI



I

AB The title compds. [I; Ar = 1,2-benzisothiazoyl, 1,2-benzisothiazoyl -1-oxide, naphthyl, pyridyl, etc.; with the proviso that Ar can not be attached to the piperazine ring via a Ph ring of Ar; Y = N, CH; A = (CH2)nCH2 (wherein n = 1-4, one of the CH2 groups that is not adjacent to the piperazine nitrogen can be replaced by an oxygen atom); R2, R3 = H, alkyl, fluoroalkyl, alkoxy, etc.; Q = (un)satd. (un)substituted 5-7 membered monocyclic heterocyclic ring contg. 1-3 heteroatoms selected from O, N and S], useful in the treatment of central nervous system disorders, were prepd. Thus, reacting 3-methylbut-2-enoic acid (2-{2-[4-(1,2-benzisothiazol-3-yl)-piperazin-1-yl]ethyl}phenyl)amide (prepn. given) with AlCl3 in C6H5Cl afforded 8-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-

yl]ethyl}-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one which showed Ki of .ltoreq. 1 .mu.M against dopamine D2 receptor binding, and Ki of .ltoreq. 1 .mu.M against 5-HT2A receptor binding. The pharmaceutical compn. comprising the compd. I is claimed.

IT **677708-42-8P 677708-43-9P 677708-44-0P 677708-45-1P**
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclic substituted piperazines for the treatment of schizophrenia)

RN 677708-42-8 CAPLUS
CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-benzoyl-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-43-9 CAPLUS
CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-44-0 CAPLUS
CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(2,5-dimethoxybenzoyl)-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-45-1 CAPLUS
CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(cyclohexylcarbonyl)-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



IT **677708-40-6P**
RL: CRT (Combinatorial reactant); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of heterocyclic substituted piperazines for the treatment of schizophrenia)
RN 677708-40-6 CAPLUS
CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



IT **677708-34-8P 677708-39-3P 677708-48-4P**
677708-49-5P 677708-51-9P 677708-53-1P
677708-58-6P 677708-86-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of heterocyclic substituted piperazines for the treatment of schizophrenia)

RN 677708-34-8 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 677708-39-3 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-phenyl- (9CI) (CA INDEX NAME)



RN 677708-48-4 CAPLUS
CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-fluoro-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-49-5 CAPLUS
CN 2(1H)-Quinolinone, 6-fluoro-8-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-51-9 CAPLUS
CN 2(1H)-Quinolinone, 8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-53-1 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 677708-58-6 CAPLUS
CN Quinoline, 8-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 677708-86-0 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-fluoro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



IT **677708-35-9P 677708-36-0P 677708-37-1P**
677708-38-2P 677708-41-7P 677708-46-2P
677708-47-3P 677708-50-8P 677708-52-0P
677708-54-2P 677708-55-3P 677708-56-4P
677708-57-5P 677708-59-7P 677708-60-0P
677708-61-1P 677708-62-2P 677708-63-3P
677708-64-4P 677708-65-5P 677708-66-6P
677708-67-7P 677708-68-8P 677708-69-9P
677708-70-2P 677708-71-3P 677708-92-8P
677708-93-9P 677708-94-0P 677708-95-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclic substituted piperazines for the treatment of schizophrenia)
RN 677708-35-9 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,4,4-trimethyl- (9CI) (CA INDEX NAME)



RN 677708-36-0 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-fluoro-3,4-dihydro-4,4-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 677708-37-1 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 677708-38-2 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-41-7 CAPLUS
CN Quinoline, 1-acetyl-8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-46-2 CAPLUS
CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-47-3 CAPLUS
CN 2(1H)-Quinolinone, 6-fluoro-3,4-dihydro-4,4-dimethyl-8-[2-[4-(1-oxido-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 677708-50-8 CAPLUS
CN Quinoline, 1-acetyl-6-fluoro-8-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4,4-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 677708-52-0 CAPLUS
CN Quinoline, 1-acetyl-8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,4-tetrahydro-4,4-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 677708-54-2 CAPLUS
CN Quinoline, 1-acetyl-8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4,4,5-trimethyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 677708-55-3 CAPLUS
CN Quinoline, 1-acetyl-8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 677708-56-4 CAPLUS
CN Quinoline, 1-acetyl-8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-fluoro-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-57-5 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 677708-59-7 CAPLUS
CN Quinoline, 1-acetyl-8-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4,4,5-trimethyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 677708-60-0 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-6-fluoro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-61-1 CAPLUS
CN Quinoline, 1-acetyl-8-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-6-fluoro-1,2,3,4-tetrahydro-4,4-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 677708-62-2 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 677708-63-3 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-64-4 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 677708-65-5 CAPLUS
CN 4H-Cyclopenta[c]quinolin-4-one, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 677708-66-6 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3-ethyl-4-methyl- (9CI) (CA INDEX NAME)



RN 677708-67-7 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 677708-68-8 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 677708-69-9 CAPLUS
CN 6(5H)-Phenanthridinone, 4-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 677708-70-2 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 677708-71-3 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 677708-92-8 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 677708-93-9 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-94-0 CAPLUS
CN 2(1H)-Quinolinone, 8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-6-chloro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-95-1 CAPLUS
CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



IT **677708-81-5P 677708-82-6P 677708-83-7P**

677708-84-8P 677708-85-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of heterocyclic substituted piperazines for the treatment of schizophrenia)

RN 677708-81-5 CAPLUS
CN Quinoline, 6-fluoro-8-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-82-6 CAPLUS
CN Quinoline, 8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-83-7 CAPLUS
CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 677708-84-8 CAPLUS
CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4-phenyl- (9CI) (CA INDEX NAME)



RN 677708-85-9 CAPLUS
CN Quinoline, 8-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-6-fluoro-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:267327 CAPLUS
DN 140:287412
TI Preparation of piperazines as dopamine D2 and serotonin 5HT2A receptors inhibitors for the treatment of central nervous system disorders, in particular schizophrenia
IN Andreana, Tonja Lynn; Cho, Stephen Sung Yong; Graham, James Michael; Gregory, Tracy Fay; Howard, Harry Ralph, Jr.; Kornberg, Brian Edward; Nikam, Sham Shridhar; Pflum, Derek Andrew
PA Warner-Lambert Company LLC, USA
SO PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026864	A1	20040401	WO 2003-IB3902	20030905
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2499326	AA	20040401	CA 2003-2499326	20030905
	EP 1546143	A1	20050629	EP 2003-797433	20030905
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003014393	A	20050719	BR 2003-14393	20030905
	US 2004138230	A1	20040715	US 2003-660908	20030912
PRAI	US 2002-411475P	P	20020917		
	US 2002-416355P	P	20021004		
	WO 2003-IB3902	W	20030905		

OS MARPAT 140:287412

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X =S, O, SO, SO2, CH2, NH and derivs.; Y, Z = independently N or CH; A = (CH2)mCH2, (CH2)mO, (CH2)mNR9, (CH2)mC(R7R8); R7, R8 = independently (un)substituted alkyl, alkoxy, or CR7R8 = carbonyl; m = 1-4; R4, R5 = independently H, (un)substituted alkyl, alkoxy, or when X = NR6 and derivs., CR4R5R6N = 4-7 membered heterocyclyl ring, with the proviso that when R9R4 or R9R5 = a ring, the other of R4 and R5 is absent; R9 = H, (un)substituted alkyl, alkoxy; R6 = H, (un)substituted alkyl, alkoxy; R1 = H, (un)substituted alkyl; R2, R3 = independently H, halo, hetero/aryl, (un)substituted aryl/heteroarylalkyl, alkoxy, etc.; V, W = independently CH2 and derivs. or CH and derivs.; and their pharmaceutically acceptable salts] were prepd. s dopamine D2 and serotonin 5HT2A receptors inhibitors for treating central nervous system disorders, in particular schizophrenia (no data). For example, II.bul.MeSO3H was prepd. by acylation of 3-chloro-2-methylaniline with 3,3-diethylacryloyl chloride, one-pot Friedel-Craft alkylation with chloroacetyl chloride and cyclization in the presence of AlCl3 to chloroacetylquinoline intermediate, redn. to chloroethylquinoline III, alkylation of 3-(piperazin-1-yl)benzo[d]isothiazole hydrochloride with III, followed by salt formation of II with methanesulfonic acid. II acted as dopamine D2 and serotonin 5HT2A receptors inhibitors with a Ki value of 0.9 nm and 1 nM, resp. Thus, I and their formulations are useful for treating central nervous system disorders, in particular schizophrenia and depression.

IT **676117-35-4P**, 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetamide **676117-36-5P**, 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]propionamide **676117-37-6P**, 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]-N-phenylpropionamide **676117-38-7P**, [6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetic acid ethyl ester **676117-39-8P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3-methyl-3,4-dihydro-1H-quinolin-2-one **676117-40-1P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-1-(2-oxo-2-phenylethyl)-3,4-dihydro-1H-quinoline-2-one **676117-41-2P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(2-methoxyethyl)-3-methyl-3,4-dihydro-1H-quinolin-2-one **676117-42-3P**, 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]propionitrile **676117-43-4P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-isobutyl-3-methyl-3,4-dihydro-1H-quinolin-2-one **676117-44-5P**, 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetamide **676117-45-6P**, [6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetic acid ethyl ester **676117-46-7P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676117-47-8P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-1-(2-oxo-2-phenylethyl)-3,4-dihydro-1H-quinolin-2-one **676117-48-9P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(methoxymethyl)-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676117-49-0P**,

6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(2-methoxyethyl)-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676117-50-3P**, 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]propionitrile **676117-51-4P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676117-52-5P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-isobutyl-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676117-53-6P**, 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]propionamide **676117-54-7P**, 2-[6-[2-[4-(1,2-Benzoisothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]-N-phenylpropionamide **676117-55-8P**, [6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetic acid ethyl ester **676117-56-9P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-4-methyl-3,4-dihydro-1H-quinolin-2-one **676117-57-0P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-1-(2-oxo-2-phenylethyl)-3,4-dihydro-1H-quinolin-2-one **676117-58-1P**, 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]propionitrile **676117-59-2P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-4-methyl-3,4-dihydro-1H-quinolin-2-one **676117-60-5P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-1-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-quinolin-2-one **676117-61-6P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-isobutyl-4-methyl-3,4-dihydro-1H-quinolin-2-one **676117-62-7P**, 2-[6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetamide **676117-63-8P**, 2-[6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]propionamide **676117-64-9P**, 2-[6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]-N-phenylpropionamide **676117-65-0P**, [6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetic acid ethyl ester **676117-66-1P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-4-methyl-3,4-dihydro-1H-quinolin-2-one **676117-67-2P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1-(2-methoxyethyl)-4-methyl-3,4-dihydro-1H-quinolin-2-one **676117-68-3P**, 2-[6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]propionitrile **676117-69-4P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-4-methyl-3,4-dihydro-1H-quinolin-2-one **676117-70-7P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1-isobutyl-4-methyl-3,4-dihydro-1H-quinolin-2-one **676117-71-8P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dimethyl-1H-quinolin-2-one **676117-72-9P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-[2-(2-hydroxyethoxy)ethyl]-3,4-dimethyl-1H-quinolin-2-one **676117-73-0P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(2-methoxyethyl)-3,4-dimethyl-1H-quinolin-2-one **676117-74-1P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-3,4-dimethyl-1H-quinolin-2-one **676117-75-2P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1-(2,2,2-trifluoroethyl)-1H-quinolin-2-one **676117-76-3P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-isobutyl-3,4-dimethyl-1H-quinolin-2-one **676117-77-4P**, 2-[6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-2-oxo-2H-quinolin-1-yl]acetamide **676117-78-5P**, 2-[6-[2-[4-

(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-2-oxo-2H-quinolin-1-yl]propionamide **676117-79-6P**, [6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-2-oxo-2H-quinolin-1-yl]acetic acid ethyl ester **676117-80-9P**, 2-[6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-2-oxo-2H-quinolin-1-yl]propionic acid methyl ester **676117-81-0P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dimethyl-1H-quinolin-2-one **676117-82-1P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1-(2-oxo-2-phenylethyl)-1H-quinolin-2-one **676117-83-2P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1-(2-methoxyethyl)-3,4-dimethyl-1H-quinolin-2-one **676117-84-3P**, 2-[6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-2-oxo-2H-quinolin-1-yl]propionitrile **676117-85-4P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-3,4-dimethyl-1H-quinolin-2-one **676117-86-5P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1-(2,2,2-trifluoroethyl)-1H-quinolin-2-one **676117-87-6P**, [6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetic acid ethyl ester **676117-88-7P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-1-pentyl-3,4-dihydro-1H-quinolin-2-one **676117-89-8P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-1-(3-methylbutyl)-3,4-dihydro-1H-quinolin-2-one **676117-90-1P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(2-ethylbutyl)-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-91-2P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(2-ethoxyethyl)-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-92-3P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(2,2-dimethylpropyl)-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-93-4P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-cyclohexylmethyl-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-94-5P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-cyclobutylmethyl-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-95-6P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-isobutyl-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-96-7P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(n-butyl)-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-97-8P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-cyclobutyl-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of piperazines for treating of central nervous system disorders, in particular schizophrenia)

RN 676117-35-4 CAPLUS

CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676117-36-5 CAPLUS
CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,3-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676117-37-6 CAPLUS
CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,3-dimethyl-2-oxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 676117-38-7 CAPLUS
CN 1(2H)-Quinolineacetic acid, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 676117-39-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dihydro-3-methyl- (9CI) (CA INDEX NAME)



RN 676117-40-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl-1-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 676117-41-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1-(2-methoxyethyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 676117-42-3 CAPLUS
CN 1(2H)-Quinolineacetonitrile, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,3-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676117-43-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 676117-44-5 CAPLUS
CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676117-45-6 CAPLUS
CN 1(2H)-Quinolineacetic acid, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 676117-46-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-47-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl-1-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 676117-48-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1-(methoxymethyl)-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-49-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1-(2-methoxyethyl)-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-50-3 CAPLUS
CN 1(2H)-Quinolineacetonitrile, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,3,3-trimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676117-51-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-ethyl-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-52-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 676117-53-6 CAPLUS
CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,4-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676117-54-7 CAPLUS
CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,4-dimethyl-2-oxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 676117-55-8 CAPLUS
CN 1(2H)-Quinolineacetic acid, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 676117-56-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 676117-57-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-1-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 676117-58-1 CAPLUS
CN 1(2H)-Quinolineacetonitrile, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,4-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676117-59-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-ethyl-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 676117-60-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 676117-61-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 676117-62-7 CAPLUS
CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676117-63-8 CAPLUS
CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,4-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676117-64-9 CAPLUS
CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,4-dimethyl-2-oxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 676117-65-0 CAPLUS
CN 1(2H)-Quinolineacetic acid, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 676117-66-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 676117-67-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1-(2-methoxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 676117-68-3 CAPLUS
CN 1(2H)-Quinolineacetonitrile, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,4-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676117-69-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1-ethyl-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 676117-70-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 676117-71-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-72-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-[2-(2-hydroxyethoxy)ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-73-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(2-methoxyethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-74-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-ethyl-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-75-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 676117-76-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 676117-77-4 CAPLUS
CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676117-78-5 CAPLUS
CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-.alpha.,3,4-trimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676117-79-6 CAPLUS
CN 1(2H)-Quinolineacetic acid, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 676117-80-9 CAPLUS
CN 1(2H)-Quinolineacetic acid, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-.alpha.,3,4-trimethyl-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 676117-81-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-82-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-1-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 676117-83-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1-(2-methoxyethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-84-3 CAPLUS
CN 1(2H)-Quinolineacetonitrile, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-.alpha.,3,4-trimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676117-85-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1-ethyl-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-86-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 676117-87-6 CAPLUS
CN 1(2H)-Quinolineacetic acid, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 676117-88-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-1-pentyl- (9CI) (CA INDEX NAME)



RN 676117-89-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-1-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 676117-90-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(2-ethylbutyl)-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676117-91-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(2-ethoxyethyl)-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676117-92-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(2,2-dimethylpropyl)-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676117-93-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(cyclohexylmethyl)-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676117-94-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(cyclobutylmethyl)-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676117-95-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 676117-96-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-butyl-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676117-97-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-cyclobutyl-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



IT **676115-67-6P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one **676115-82-5P** **676117-11-6P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one
RL: CRT (Combinatorial reactant); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; prepn. of piperazines for treating of central nervous system disorders, in particular schizophrenia)
RN 676115-67-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 676115-82-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-11-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



IT **676116-01-1P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one
676116-05-5P, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-7-chloro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one
676116-14-6P, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-7-fluoro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one
676116-82-8P, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-7-fluoro-1,4,4-trimethyl-3,4-dihydro-1H-quinolin-2-one
676116-91-9P, 1-[6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-3,3-dimethyl-3,4-dihydro-2H-quinolin-1-yl]ethanone
676116-95-3P, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-1,3,3-trimethyl-1,2,3,4-tetrahydroquinoline
676117-13-8P, 8-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1,2,3,5-tetrahydrocyclopenta[c]quinolin-4-one
676118-30-2P, 8-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propoxy]-1,2,3,5-tetrahydrocyclopenta[c]quinolin-4-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; prepn. of piperazines for treating of central nervous

system disorders, in particular schizophrenia)

RN 676116-01-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-05-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-chloro-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-14-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-fluoro-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-82-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-7-fluoro-3,4-dihydro-1,4,4-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-91-9 CAPLUS
CN Quinoline, 1-acetyl-6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,4-tetrahydro-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-95-3 CAPLUS
CN Quinoline, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,4-tetrahydro-1,3,3-trimethyl- (9CI) (CA INDEX NAME)



RN 676117-13-8 CAPLUS
CN 4H-Cyclopenta[c]quinolin-4-one, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 676118-30-2 CAPLUS
CN 4H-Cyclopenta[c]quinolin-4-one, 8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propoxy]-1,2,3,5-tetrahydro- (9CI) (CA INDEX NAME)



IT **134017-32-6P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one **676115-68-7P 676115-69-8P 676115-70-1P 676115-72-3P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1,4-dimethyl-3,4-

dihydro-1H-quinolin-2-one **676115-73-4P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676115-74-5P 676115-77-8P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one **676115-78-9P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676115-79-0P 676115-85-8P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1,3,3,4,4-pentamethyl-3,4-dihydro-1H-quinolin-2-one **676115-88-1P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,3,4-trimethyl-3,4-dihydro-1H-quinolin-2-one **676115-92-7P**, 6-[2-[4-(1H-Indazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one **676115-94-9P**, 6-[2-[4-(1H-Indazol-3-yl)piperazin-1-yl]ethyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676115-95-0P**, 6-[2-[4-(1H-Indazol-3-yl)piperazin-1-yl]ethyl]-1,4,4-trimethyl-3,4-dihydro-1H-quinolin-2-one **676115-96-1P**, 6-[2-[4-(1H-Indazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one **676115-97-2P**, 6-[2-[4-(1H-Indazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676115-98-3P**, 6-[2-[4-(1H-Indazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676115-99-4P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1,3,3,4,4-pentamethyl-3,4-dihydro-1H-quinolin-2-one hydrochloride **676116-00-0P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3,4-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-04-4P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one mesylate **676116-06-6P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-7-chloro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one methanesulfonate **676116-10-2P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-7-fluoro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one hydrochloride **676116-15-7P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-7-fluoro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one methanesulfonate **676116-16-8P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-8-ethyl-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-20-4P 676116-24-8P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-8-ethyl-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-25-9P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-26-0P**, 6-[2-[4-(5-Methoxybenzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-28-2P**, 6-[2-[4-(7-Methoxybenzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-29-3P**, 6-[2-[4-(5-Fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-31-7P**, 6-[2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-33-9P**, 6-[2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-34-0P**, 6-[2-[4-(5-Chloro-benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-35-1P**, 6-[2-[4-(7-Fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-37-3P**, 6-[2-[4-(6-Methyl-benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-39-5P**, 6-[2-[4-(6-Fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-40-8P**, 6-[2-[4-(5-Fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1,4,4,8-tetramethyl-3,4-dihydro-1H-quinolin-2-one

hydrochloride **676116-41-9P**, 1-Ethyl-6-[2-[4-(5-fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one hydrochloride **676116-42-0P**, 6-[2-[4-(5-Fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-1-(n-propyl)-3,4-dihydro-1H-quinolin-2-one hydrochloride **676116-43-1P**, 6-[2-[4-(5-Fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-isopropyl-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one hydrochloride **676116-44-2P**, 6-[2-[4-(5-Fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-methoxymethyl-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one hydrochloride **676116-45-3P**, 1-(2-Ethoxyethyl)-6-[2-[4-(5-fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one hydrochloride **676116-52-2P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-55-5P**, 6-[3-[4-(1H-Indazol-3-yl)piperazin-1-yl]propyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-56-6P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-7-chloro-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-59-9P**, 6-[3-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]propyl]-7-chloro-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-60-2P**, 6-[3-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]propyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one **676116-61-3P**, 6-[3-[4-(1H-Indazol-3-yl)piperazin-1-yl]propyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one **676116-62-4P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-65-7P**, 6-[3-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]propyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-66-8P**, 6-[3-[4-(1H-Indazol-3-yl)piperazin-1-yl]propyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-67-9P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one **676116-70-4P**, 6-[3-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]propyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one **676116-71-5P**, 6-[3-[4-(1H-Indazol-3-yl)piperazin-1-yl]propyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one **676116-72-6P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-(4S)-methyl-3,4-dihydro-1H-quinolin-2-one **676116-74-8P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-(4R)-methyl-3,4-dihydro-1H-quinolin-2-one **676116-76-0P** **676116-77-1P** **676116-78-2P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-7-fluoro-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-84-0P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-7-fluoro-1,4,4-trimethyl-3,4-dihydro-1H-quinolin-2-one mesylate **676116-85-1P**, 1-[6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-7-fluoro-4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl]ethanone **676116-88-4P**, 1-[6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl]ethanone **676116-94-2P**, 1-[6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-3,3-dimethyl-3,4-dihydro-2H-quinolin-1-yl]ethanone mesylate **676116-97-5P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-1,3,3-trimethyl-1,2,3,4-tetrahydroquinoline mesylate **676116-98-6P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-8-chloro-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676117-01-4P**, 6-[3-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]propyl]-8-chloro-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676117-02-5P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-05-8P**, 6-[3-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]propyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-06-9P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-8-ethyl-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one

676117-09-2P, 6-[3-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]propyl]-8-ethyl-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676117-10-5P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-1H-quinolin-2-one **676117-12-7P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-ethyl-1H-quinolin-2-one **676117-14-9P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-ethyl-4-methyl-1H-quinolin-2-one **676117-15-0P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-(n-propyl)-1H-quinolin-2-one **676117-16-1P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-isopropyl-1H-quinolin-2-one **676117-17-2P**, 2-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-7,8,9,10-tetrahydro-5H-phenanthridin-6-one **676117-18-3P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-trifluoromethyl-1H-quinolin-2-one **676117-19-4P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-phenyl-1H-quinolin-2-one **676117-20-7P**, 9-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one **676117-23-0P**, 9-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1,1-dimethyl-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one hydrochloride **676117-27-4P**, 8-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-6,6-dimethyl-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one hydrochloride **676117-98-9P**, 6-[2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one **676117-99-0P**, 6-[2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one **676118-01-7P**, 6-[2-[4-(5-Chloro-benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one **676118-02-8P**, 6-[2-[4-(5-Methoxy-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one **676118-03-9P**, 6-[2-[4-(7-Fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one **676118-05-1P**, 6-[2-[4-(6-Fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one **676118-06-2P**, 6-[2-[4-(5-Fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one **676118-09-5P**, 6-[2-[4-(1H-Indazol-3-yl)-piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one **676118-10-8P**, 8-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-6-methyl-3,5-dihydro-1H-furo[3,4-c]quinolin-4-one **676118-15-3P**, 8-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,5-dihydro-1H-furo[3,4-c]quinolin-4-one **676118-17-5P**, 8-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-3,5-dihydro-1H-furo[3,4-c]quinolin-4-one **676118-19-7P**, 8-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,5-dihydro-1H-furo[3,4-c]quinolin-4-one **676118-23-3P**, 8-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-2-methyl-1,2,3,5-tetrahydropyrrolo[3,4-c]quinolin-4-one **676118-27-7P**, 8-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-2-methyl-1,2,3,5-tetrahydropyrrolo[3,4-c]quinolin-4-one **676118-28-8P**, 8-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-5-ethyl-1,2,3,5-tetrahydrocyclopenta[c]quinolin-4-one **676118-29-9P**, 8-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-5-methyl-1,2,3,5-tetrahydrocyclopenta[c]quinolin-4-one **676118-31-3P**, 8-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propoxy]-1,2,3,5-tetrahydrocyclopenta[c]quinolin-4-one methanesulfonate **676118-34-6P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1,4,4-trimethyl-3,4-dihydro-1H-quinolin-2-one **676118-35-7P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1,3,3,4,4-pentamethyl-3,4-dihydro-1H-quinolin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(drug candidate; prepn. of piperazines for treating of central nervous system disorders, in particular schizophrenia)

RN 134017-32-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 676115-68-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 676115-69-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 676115-70-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,4-dimethyl-, hydrochloride (10:11) (9CI) (CA INDEX NAME)



●11/10 HCl

RN 676115-72-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676115-73-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676115-74-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,4,4-trimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 676115-77-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl- (9CI) (CA INDEX NAME)



RN 676115-78-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 676115-79-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 676115-85-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,3,3,4,4-pentamethyl- (9CI) (CA INDEX NAME)



RN 676115-88-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3,4-trimethyl- (9CI) (CA INDEX NAME)



RN 676115-92-7 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 676115-94-9 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676115-95-0 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-1,4,4-trimethyl- (9CI) (CA INDEX NAME)



RN 676115-96-1 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 676115-97-2 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 676115-98-3 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676115-99-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,3,3,4,4-pentamethyl-, monohydrochloride (9CI) (CA INDEX

NAME)



● HCl

RN 676116-00-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3,4-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-04-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-, mono(methanesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 676116-01-1
CMF C25 H30 N4 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 676116-06-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-chloro-3,4-dihydro-4,4,8-trimethyl-, mono(methanesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 676116-05-5
CMF C25 H29 Cl N4 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 676116-10-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-fluoro-3,4-dihydro-4,4,8-trimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 676116-15-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-fluoro-3,4-dihydro-4,4,8-trimethyl-, mono(methanesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 676116-14-6
CMF C25 H29 F N4 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 676116-16-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-8-ethyl-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-20-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-8-chloro-3,4-dihydro-4,4-dimethyl-, hydrochloride (5:6) (9CI) (CA INDEX NAME)



●6/5 HCl

RN 676116-24-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-8-ethyl-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-25-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-26-0 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(5-methoxy-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-28-2 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(7-methoxy-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-29-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-31-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(5-fluoro-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-33-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-

piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-34-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(5-chloro-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-35-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(7-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-37-3 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-4,4,8-trimethyl-6-[2-[4-(6-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 676116-39-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-40-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,4,4,8-tetramethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 676116-41-9 CAPLUS
CN 2(1H)-Quinolinone, 1-ethyl-6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 676116-42-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 676116-43-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 676116-44-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1-(methoxymethyl)-4,4,8-trimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 676116-45-3 CAPLUS
CN 2(1H)-Quinolinone, 1-(2-ethoxyethyl)-6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-, monohydrochloride

(9CI) (CA INDEX NAME)



● HCl

RN 676116-52-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-55-5 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-6-[3-[4-(1H-indazol-3-yl)-1-piperazinyl]propyl]-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-56-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-7-chloro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-59-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-7-

chloro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-60-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 676116-61-3 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-6-[3-[4-(1H-indazol-3-yl)-1-piperazinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 676116-62-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-65-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-66-8 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-6-[3-[4-(1H-indazol-3-yl)-1-piperazinyl]propyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-67-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-3-methyl- (9CI) (CA INDEX NAME)



RN 676116-70-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-3-methyl- (9CI) (CA INDEX NAME)



RN 676116-71-5 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-6-[3-[4-(1H-indazol-3-yl)-1-piperazinyl]propyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 676116-72-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676116-74-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676116-76-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676116-77-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676116-78-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-7-fluoro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-84-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-7-fluoro-3,4-dihydro-1,4,4-trimethyl-, mono(methanesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 676116-82-8
CMF C26 H31 F N4 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 676116-85-1 CAPLUS
CN Quinoline, 1-acetyl-6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-7-fluoro-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-88-4 CAPLUS
CN Quinoline, 1-acetyl-6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-94-2 CAPLUS

CN Quinoline, 1-acetyl-6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,4-tetrahydro-3,3-dimethyl-, mono(methanesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 676116-91-9
CMF C27 H34 N4 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 676116-97-5 CAPLUS
CN Quinoline, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,4-tetrahydro-1,3,3-trimethyl-, mono(methanesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 676116-95-3
CMF C26 H34 N4 S



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 676116-98-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-8-chloro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-01-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-8-chloro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-02-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676117-05-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676117-06-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-8-ethyl-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-09-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-8-ethyl-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-10-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 676117-12-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 676117-14-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3-ethyl-4-methyl- (9CI) (CA INDEX NAME)



RN 676117-15-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 676117-16-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 676117-17-2 CAPLUS
CN 6(5H)-Phenanthridinone, 2-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 676117-18-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 676117-19-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 676117-20-7 CAPLUS
CN 1H,5H-Benzo[ij]quinolizin-5-one, 9-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-2,3,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 676117-23-0 CAPLUS
CN 1H,5H-Benzo[ij]quinolizin-5-one, 9-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-2,3,6,7-tetrahydro-7,7-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 676117-27-4 CAPLUS
CN 4H-Pyrrolo[3,2,1-ij]quinolin-4-one, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,5,6-tetrahydro-6,6-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 676117-98-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(5-fluoro-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-99-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676118-01-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(5-chloro-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676118-02-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(5-methoxy-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676118-03-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(7-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676118-05-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676118-06-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676118-09-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676118-10-8 CAPLUS
CN Furo[3,4-c]quinolin-4(1H)-one, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,5-dihydro-6-methyl- (9CI) (CA INDEX NAME)



RN 676118-15-3 CAPLUS
CN Furo[3,4-c]quinolin-4(1H)-one, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,5-dihydro- (9CI) (CA INDEX NAME)



RN 676118-17-5 CAPLUS
CN Furo[3,4-c]quinolin-4(1H)-one, 8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,5-dihydro- (9CI) (CA INDEX NAME)



RN 676118-19-7 CAPLUS
CN Furo[3,4-c]quinolin-4(1H)-one, 8-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,5-dihydro- (9CI) (CA INDEX NAME)



RN 676118-23-3 CAPLUS
CN 4H-Pyrrolo[3,4-c]quinolin-4-one, 8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,5-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 676118-27-7 CAPLUS
CN 4H-Pyrrolo[3,4-c]quinolin-4-one, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,5-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 676118-28-8 CAPLUS
CN 4H-Cyclopenta[c]quinolin-4-one, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-5-ethyl-1,2,3,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 676118-29-9 CAPLUS
CN 4H-Cyclopenta[c]quinolin-4-one, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,5-tetrahydro-5-methyl- (9CI) (CA INDEX NAME)



RN 676118-31-3 CAPLUS
CN 4H-Cyclopenta[c]quinolin-4-one, 8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propoxy]-1,2,3,5-tetrahydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676118-30-2
CMF C26 H28 N4 O2 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 676118-34-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,4,4-trimethyl- (9CI) (CA INDEX NAME)



RN 676118-35-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,3,3,4,4-pentamethyl- (9CI) (CA INDEX NAME)



IT **134017-21-3**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one **134017-22-4**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one **134017-24-6**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one
RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)
(prepn. of piperazines for treating of central nervous system disorders, in particular schizophrenia)

RN 134017-21-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 134017-22-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl- (9CI) (CA INDEX NAME)



RN 134017-24-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1991:492295 CAPLUS
DN 115:92295
TI Preparation of heteroarylpiperazines as antipsychotic agents
IN Howard, Harry R.
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 409435	A1	19910123	EP 1990-307166	19900629
	EP 409435	B1	19941026		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 9100863	A1	19910124	WO 1989-US2954	19890707
	W: FI, HU, NO, RO, SU, US				
	ES 2062374	T3	19941216	ES 1990-307166	19900629
	JP 03044388	A2	19910226	JP 1990-176120	19900703
	JP 07017633	B4	19950301		
	CA 2020611	AA	19910108	CA 1990-2020611	19900706
	US 5350747	A	19940927	US 1992-836019	19920220
PRAI	WO 1989-US2954	A	19890707		

OS MARPAT 115:92295
GI



I



II



III



IV

AB The title compds. [I; W1 = CR2R3; W2 = CR4R5; W3 = CR6R7; 1 of W1-W3 may be absent; R1 = (substituted) benzisoxazolyl, benzisothiazolyl, benzopyrazolyl; R2-R7 = H, alkyl, 2 of them may form alkylene, alkenylene; X1 = H, halo, C1-4 alkyl, alkoxy, NO2, cyano, etc.; Y1 = H, C1-4 alkyl, (substituted) Ph, etc.; X1Y1 = heterocyclyl; Z = C1-6 alkylene], useful as antipsychotic agents (no data), were prepd. A mixt. of piperazine deriv. II, quinolinone III (prepn. given), Na2CO3, and KI in MIBK was heated at 90.degree. under N to give 13% title compd. IV, sepd. as HCl.1/2 H2O. Also prepd. were 17 addnl. I and numerous intermediates.

IT **133999-10-7P 134017-19-9P 134017-20-2P**
134017-21-3P 134017-22-4P 134017-23-5P
134017-24-6P 134017-25-7P 134017-26-8P
134017-27-9P 134017-28-0P 134017-29-1P
134017-30-4P 134017-31-5P 134017-32-6P
135357-15-2P 135357-16-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antipsychotic agent)

RN 133999-10-7 CAPLUS

CN 2(1H)-Quinolinone, 7-chloro-3,4-dihydro-6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 134017-19-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134017-20-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 134017-21-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 134017-22-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl- (9CI) (CA INDEX NAME)



RN 134017-23-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-7-methyl- (9CI) (CA INDEX NAME)



RN 134017-24-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 134017-25-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 134017-26-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,7-dimethyl- (9CI) (CA INDEX NAME)



RN 134017-27-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-

3,4-dihydro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 134017-28-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,3,3-trimethyl- (9CI) (CA INDEX NAME)



RN 134017-29-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,7-trimethyl- (9CI) (CA INDEX NAME)



RN 134017-30-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-chloro-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 134017-31-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-chloro-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 134017-32-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 135357-15-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 135357-16-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	84.00	426.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.95	-12.41

FILE 'CAOLD' ENTERED AT 18:59:32 ON 30 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 18:36:02 ON 30 SEP 2005)

FILE 'REGISTRY' ENTERED AT 18:36:18 ON 30 SEP 2005
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 1 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 18:39:13 ON 30 SEP 2005
L4 2 S L3

```
     FILE 'REGISTRY' ENTERED AT 18:44:50 ON 30 SEP 2005
L5                STRUCTURE UPLOADED
L6             12 S L5
L7            315 S L5 SSS FULL
                  SAVE L7 TEN672949/A

     FILE 'CAPLUS' ENTERED AT 18:46:21 ON 30 SEP 2005
L8             12 S L7

     FILE 'CAOLD' ENTERED AT 18:59:32 ON 30 SEP 2005

=> s l7
L9              0 L7

=> log h
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.43     426.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -12.41

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 18:59:56 ON 30 SEP 2005
```